Construction and validation of "WCH-nomogram" for predicting the prognosis after resection of colorectal liver metastases

Cancer Med. 2024 May;13(9):e7222. doi: 10.1002/cam4.7222.

Abstract

Background: The prognostic predictive tool for patients with colorectal liver metastasis (CRLM) is limited and the criteria for administering preoperative neoadjuvant chemotherapy in CRLM patients remain controversial.

Methods: This study enrolled 532 CRLM patients at West China Hospital (WCH) from January 2009 to December 2019. Prognostic factors were identified from the training cohort to construct a WCH-nomogram and evaluating accuracy in the validation cohort. Receiver operating characteristic (ROC) curve analysis was used to compare the prediction accuracy with other existing prediction tools.

Results: From the analysis of the training cohort, four independent prognostic risk factors, namely tumor marker score, KRAS mutation, primary lymph node metastasis, and tumor burden score were identified on which a WCH-nomogram was constructed. The C-index of the two cohorts were 0.674 (95% CI: 0.634-0.713) and 0.655 (95% CI: 0.586-0.723), respectively, which was better than the previously reported predication scores (CRS, m-CS and GAME score). ROC curves showed AUCs for predicting 1-, 3-, and 5-year overall survival (OS) of 0.758, 0.709, and 0.717 in the training cohort, and 0.860, 0.669, and 0.692 in the validation cohort, respectively. A cutoff value of 114.5 points was obtained for the WCH-nomogram total score based on the maximum Youden index of the ROC curve of 5-year OS. Risk stratification showed significantly better prognosis in the low-risk group, however, the high-risk group was more likely to benefit from neoadjuvant chemotherapy.

Conclusions: The WCH-nomogram demonstrates superior prognostic stratification compared to prior scoring systems, effectively identifying CRLM patients who may benefit the most from neoadjuvant chemotherapy.

Keywords: Colorectal cancer; colorectal liver metastasis; nomogram; survival.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor
  • China
  • Colorectal Neoplasms* / mortality
  • Colorectal Neoplasms* / pathology
  • Colorectal Neoplasms* / surgery
  • Female
  • Hepatectomy*
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / mortality
  • Liver Neoplasms* / secondary
  • Liver Neoplasms* / surgery
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Mutation
  • Neoadjuvant Therapy
  • Nomograms*
  • Prognosis
  • Proto-Oncogene Proteins p21(ras) / genetics
  • ROC Curve
  • Retrospective Studies
  • Risk Factors
  • Tumor Burden

Substances

  • Biomarkers, Tumor
  • Proto-Oncogene Proteins p21(ras)
  • KRAS protein, human